Non-Alcoholic Fatty Liver Disease Clinical Trial
Official title:
The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease
Non alcoholic fatty liver disease (NAFLD) imposes a high and increasing burden on the NHS,
yet there is presently no licensed treatment or validated approach to management. NAFLD
predisposes to increased risk of type 2 diabetes, increased risk of cardiovascular disease
and may progress to chronic irreversible liver disease.
In NAFLD patients, the investigators will test the hypothesis that treatment with long chain
n-3 fatty acid supplementation for 18 months favourably influences bio-markers for NAFLD and
risk factors for cardiovascular disease and type 2 diabetes.
We will recruit people with NAFLD who have been diagnosed as part of their NHS care with
having this condition. At present there is no treatment for this condition. Over time a
proportion of people with NAFLD.
Purpose and design
We are asking the research question ' Does treatment with purified long chain n-3 fatty acids
(purified fish oil) improve non alcoholic fatty liver disease and risk factors for heart
disease and type 2 (adult) diabetes that are strongly linked to this liver condition?'
Presently there is no treatment for this liver condition. Research evidence suggests that
purified long chain n-3 fatty acids might be beneficial for this condition.
To address this research question we want to undertake a randomised double blind placebo
controlled trial recruiting people who have been diagnosed with a liver biopsy as having the
liver condition.
A protocol change that were approved during in the course of the study in October 2011.
In the protocol, we have deleted information regarding liver biopsy that was to be offered at
the end of the study.
Having collated volunteer opinion and local consultant opinion, whereas a high proportion of
volunteers were happy to undergo a follow up liver biopsy, our local hepatologists now
consider that in 2011, the small risk of morbidity and mortality of volunteers undergoing
liver biopsy is unacceptable, within the context of a research study. Their opinions have
changed since 2008 when the initial LREC approval was granted.
Liver biopsy was always an optional extra and would only have been undertaken in a subgroup
of the volunteers. Therefore, removal of liver biopsy from the protocol does not affect the
validity of the study to test effects of the n-3 fatty acid intervention on biomarkers and
liver fat in people with non alcoholic fatty liver disease.
Besides removal of liver biopsy from the protocol, we have clarified in the protocol, the end
points of the study and numbers randomised to either n-3 fatty acid or placebo (n=100, as
always intended). We have also made it clear in the amendment that measurement of liver fat
is also a primary outcome of the study. (We already have permission to undertake this test
but it was uncertain when the study was approved that we would have sufficient funding for
this expensive test and it was originally not a primary outcome).
We have therefore added a power calculation (and cited the relevant literature) to show that
with a sample size of n=100 people, based upon the known treatment effects of n-3 fatty acids
on liver fat, we have acceptable power to detect the predicted decrease in this outcome with
treatment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04671186 -
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
|
N/A | |
Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
Completed |
NCT05006885 -
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 1 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
Recruiting |
NCT05618626 -
Prevention of NAFLD and CVD Through Lifestyle Intervention
|
N/A | |
Completed |
NCT03256526 -
6-week Safety and PD Study in Adults With NAFLD
|
Phase 2 | |
Enrolling by invitation |
NCT06152991 -
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
|
Phase 3 | |
Completed |
NCT03681457 -
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
|
Phase 1 | |
Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT03060694 -
Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
|
||
Completed |
NCT02526732 -
Hepatic Inflammation and Physical Performance in Patients With NASH
|
N/A | |
Recruiting |
NCT01988441 -
The Influence of Autophagy on Fatty Liver
|
||
Recruiting |
NCT01680003 -
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT01712711 -
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Recruiting |
NCT00941642 -
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
|
Phase 4 |